Brokerages Set Repligen Co. (NASDAQ:RGEN) Price Target at $185.20

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $185.20.

Several research firms recently weighed in on RGEN. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Thursday, December 19th. Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Wells Fargo & Company initiated coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock.

Repligen Stock Performance

Shares of Repligen stock opened at $146.95 on Wednesday. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -397.15, a PEG ratio of 4.64 and a beta of 0.96. The firm has a fifty day moving average of $144.23 and a two-hundred day moving average of $141.65.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 earnings per share. As a group, equities research analysts predict that Repligen will post 1.54 EPS for the current year.

Hedge Funds Weigh In On Repligen

A number of large investors have recently bought and sold shares of RGEN. Andra AP fonden bought a new stake in shares of Repligen in the second quarter worth $25,000. International Assets Investment Management LLC bought a new stake in Repligen during the 2nd quarter worth about $33,000. UMB Bank n.a. lifted its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV bought a new position in shares of Repligen in the 3rd quarter valued at about $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.